These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
561 related articles for article (PubMed ID: 33579557)
1. Which adjuvant treatment for patients with BRAF Funck-Brentano E; Malissen N; Roger A; Lebbé C; Deilhes F; Frénard C; Dréno B; Meyer N; Grob JJ; Tétu P; Saiag P Ann Dermatol Venereol; 2021 Sep; 148(3):145-155. PubMed ID: 33579557 [TBL] [Abstract][Full Text] [Related]
2. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. Long GV; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Schachter J; Schadendorf D; Lesimple T; Plummer R; Ji R; Zhang P; Mookerjee B; Legos J; Kefford R; Dummer R; Kirkwood JM N Engl J Med; 2017 Nov; 377(19):1813-1823. PubMed ID: 28891408 [TBL] [Abstract][Full Text] [Related]
3. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF Dummer R; Brase JC; Garrett J; Campbell CD; Gasal E; Squires M; Gusenleitner D; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Flaherty K; Larkin J; Robert C; Kefford R; Kirkwood JM; Hauschild A; Schadendorf D; Long GV Lancet Oncol; 2020 Mar; 21(3):358-372. PubMed ID: 32007138 [TBL] [Abstract][Full Text] [Related]
4. Comparative analysis of adjuvant therapy for stage III BRAF-mut melanoma: A real-world retrospective study from single center in China. Zhong J; Sun W; Hu T; Wang C; Yan W; Luo Z; Liu X; Xu Y; Chen Y Cancer Med; 2023 May; 12(10):11475-11482. PubMed ID: 37016119 [TBL] [Abstract][Full Text] [Related]
5. Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected Hauschild A; Dummer R; Schadendorf D; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Schachter J; Lesimple T; Plummer R; Dasgupta K; Haas T; Shilkrut M; Gasal E; Kefford R; Kirkwood JM; Long GV J Clin Oncol; 2018 Dec; 36(35):3441-3449. PubMed ID: 30343620 [TBL] [Abstract][Full Text] [Related]
6. Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma. Si L; Zhang X; Shin SJ; Fan Y; Lin CC; Kim TM; Dechaphunkul A; Maneechavakajorn J; Wong CS; Ilankumaran P; Lee DY; Gasal E; Li H; Guo J Eur J Cancer; 2020 Aug; 135():31-38. PubMed ID: 32534242 [TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAF Long GV; Saw RPM; Lo S; Nieweg OE; Shannon KF; Gonzalez M; Guminski A; Lee JH; Lee H; Ferguson PM; Rawson RV; Wilmott JS; Thompson JF; Kefford RF; Ch'ng S; Stretch JR; Emmett L; Kapoor R; Rizos H; Spillane AJ; Scolyer RA; Menzies AM Lancet Oncol; 2019 Jul; 20(7):961-971. PubMed ID: 31171444 [TBL] [Abstract][Full Text] [Related]
8. Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II). Atkinson V; Sandhu S; Hospers G; Long GV; Aglietta M; Ferrucci PF; Tulyte S; Cappellini GCA; Soriano V; Ali S; Poprach A; Cesas A; Rodriguez-Abreu D; Lau M; de Jong E; Legenne P; Stein D; King B; van Thienen JV Melanoma Res; 2020 Jun; 30(3):261-267. PubMed ID: 31895752 [TBL] [Abstract][Full Text] [Related]
9. First-line pembrolizumab versus dabrafenib/trametinib treatment for BRAF V600-mutant advanced melanoma. Kim CG; Kim M; Hwang J; Kim ST; Jung M; Kim KH; Kim KH; Chang JS; Koom WS; Roh MR; Chung KY; Kim TM; Kim SK; Lee J; Shin SJ J Am Acad Dermatol; 2022 Nov; 87(5):989-996. PubMed ID: 36068115 [TBL] [Abstract][Full Text] [Related]
10. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF Schreuer M; Jansen Y; Planken S; Chevolet I; Seremet T; Kruse V; Neyns B Lancet Oncol; 2017 Apr; 18(4):464-472. PubMed ID: 28268064 [TBL] [Abstract][Full Text] [Related]
11. Budget Impact of Dabrafenib and Trametinib in Combination as Adjuvant Treatment of BRAF V600E/K Mutation-Positive Melanoma from a U.S. Commercial Payer Perspective. Stellato D; Gerbasi ME; Ndife B; Ghate SR; Moynahan A; Mishra D; Gunda P; Koruth R; Delea TE J Manag Care Spec Pharm; 2019 Nov; 25(11):1227-1237. PubMed ID: 31663466 [TBL] [Abstract][Full Text] [Related]
12. Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF Schadendorf D; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Lesimple T; Plummer R; Schachter J; Dasgupta K; Manson S; Koruth R; Mookerjee B; Kefford R; Dummer R; Kirkwood JM; Long GV Lancet Oncol; 2019 May; 20(5):701-710. PubMed ID: 30928620 [TBL] [Abstract][Full Text] [Related]
13. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion-Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT Lancet Oncol; 2018 May; 19(5):603-615. PubMed ID: 29573941 [TBL] [Abstract][Full Text] [Related]
14. STARBOARD: encorafenib + binimetinib + pembrolizumab for first-line metastatic/unresectable Schadendorf D; Dummer R; Robert C; Ribas A; Sullivan RJ; Panella T; McKean M; Santos ES; Brill K; Polli A; Pietro AD; Ascierto PA Future Oncol; 2022 Jun; 18(17):2041-2051. PubMed ID: 35272485 [TBL] [Abstract][Full Text] [Related]
15. Novel adjuvant options for cutaneous melanoma. Dimitriou F; Long GV; Menzies AM Ann Oncol; 2021 Jul; 32(7):854-865. PubMed ID: 33771664 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials. Larkin J; Lao CD; Urba WJ; McDermott DF; Horak C; Jiang J; Wolchok JD JAMA Oncol; 2015 Jul; 1(4):433-40. PubMed ID: 26181250 [TBL] [Abstract][Full Text] [Related]
18. COLUMBUS-AD: phase III study of adjuvant encorafenib + binimetinib in resected stage IIB/IIC BRAF V600-mutated melanoma. van Akkooi AC; Hauschild A; Long GV; Mandala M; Kicinski M; Govaerts AS; Klauck I; Ouali M; Lorigan PC; Eggermont AM Future Oncol; 2023 Sep; 19(30):2017-2027. PubMed ID: 37665297 [TBL] [Abstract][Full Text] [Related]
19. Retrospective Chart Review of Dabrafenib Plus Trametinib in Patients with Metastatic BRAF V600-Mutant Melanoma Treated in the Individual Patient Program (DESCRIBE Italy). Aglietta M; Chiarion-Sileni V; Fava P; Guidoboni M; Depenni R; Minisini A; Consoli F; Ascierto P; Rinaldi G; Banzi M; Marconcini R; Gueli R; Ferraresi V; Tucci M; Tonini G; Lo Re G; Guida M; Del Vecchio M; Marcon IG; Queirolo P Target Oncol; 2021 Nov; 16(6):789-799. PubMed ID: 34755244 [TBL] [Abstract][Full Text] [Related]
20. Cost-Effectiveness Analysis of Adjuvant Therapy for BRAF-Mutant Resected Stage III Melanoma in Medicare Patients. Mojtahed SA; Boyer NR; Rao SA; Gajewski TF; Tseng J; Turaga KK Ann Surg Oncol; 2021 Dec; 28(13):9039-9047. PubMed ID: 34129153 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]